inositol and ADDH
inositol has been researched along with ADDH in 11 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors' goal was to investigate phosphatidylinositol and glutamatergic metabolism in the anterior cingulate cortex of children and adolescents with attention deficit hyperactivity disorder (ADHD) alone, children with ADHD plus bipolar disorder, and children with no axis I diagnosis." | 3.73 | Differences in brain chemistry in children and adolescents with attention deficit hyperactivity disorder with and without comorbid bipolar disorder: a proton magnetic resonance spectroscopy study. ( Aleardi, M; Biederman, J; Dougherty, M; Hammerness, P; Harpold, T; Mick, E; Moore, CM; Randall, E; Renshaw, PF; Wardrop, M; Wozniak, J, 2006) |
Research
Studies (11)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Dickstein, DP | 2 |
| Towbin, KE | 2 |
| Van Der Veen, JW | 2 |
| Rich, BA | 1 |
| Brotman, MA | 1 |
| Knopf, L | 2 |
| Onelio, L | 1 |
| Pine, DS | 2 |
| Leibenluft, E | 2 |
| Ferreira, PE | 1 |
| Palmini, A | 1 |
| Bau, CH | 1 |
| Grevet, EH | 1 |
| Hoefel, JR | 1 |
| Rohde, LA | 1 |
| Anés, M | 1 |
| Ferreira, EE | 1 |
| Belmonte-de-Abreu, P | 1 |
| Rüsch, N | 1 |
| Boeker, M | 1 |
| Büchert, M | 1 |
| Glauche, V | 1 |
| Bohrmann, C | 1 |
| Ebert, D | 2 |
| Lieb, K | 1 |
| Hennig, J | 2 |
| Tebartz Van Elst, L | 2 |
| Parikh, SV | 1 |
| LeBlanc, SR | 1 |
| Ovanessian, MM | 1 |
| Jain, M | 1 |
| Vélez, JI | 2 |
| Acosta, MT | 2 |
| Palacio, LG | 1 |
| Balog, J | 1 |
| Roessler, E | 1 |
| Pineda, D | 1 |
| Londoño, AC | 2 |
| Palacio, JD | 2 |
| Arbelaez, A | 2 |
| Lopera, F | 2 |
| Elia, J | 1 |
| Hakonarson, H | 1 |
| Seitz, C | 1 |
| Freitag, CM | 1 |
| Palmason, H | 1 |
| Meyer, J | 1 |
| Romanos, M | 1 |
| Walitza, S | 1 |
| Hemminger, U | 1 |
| Warnke, A | 1 |
| Romanos, J | 1 |
| Renner, T | 1 |
| Jacob, C | 1 |
| Lesch, KP | 1 |
| Swanson, J | 1 |
| Castellanos, FX | 2 |
| Bailey-Wilson, JE | 1 |
| Arcos-Burgos, M | 2 |
| Muenke, M | 2 |
| Pineda, DA | 1 |
| Tafazoli, S | 1 |
| O'Neill, J | 1 |
| Bejjani, A | 1 |
| Ly, R | 1 |
| Salamon, N | 1 |
| McCracken, JT | 1 |
| Alger, JR | 1 |
| Levitt, JG | 1 |
| Moore, CM | 1 |
| Biederman, J | 1 |
| Wozniak, J | 1 |
| Mick, E | 1 |
| Aleardi, M | 1 |
| Wardrop, M | 1 |
| Dougherty, M | 1 |
| Harpold, T | 1 |
| Hammerness, P | 1 |
| Randall, E | 1 |
| Renshaw, PF | 1 |
| Perlov, E | 1 |
| Philipsen, A | 1 |
| Hesslinger, B | 1 |
| Buechert, M | 1 |
| Ahrendts, J | 1 |
| Feige, B | 1 |
| Bubl, E | 1 |
| Carrey, NJ | 1 |
| MacMaster, FP | 1 |
| Gaudet, L | 1 |
| Schmidt, MH | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| Measuring Glutamate and GABA Brain Levels in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Using Magnetic Resonance Spectroscopy (MRS)[NCT04823364] | 60 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Percent Weight Change Compared to Baseline Weight
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
BMI Percentile
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
BMI Z-scores
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
Weight Change
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
Trials
2 trials available for inositol and ADDH
| Article | Year |
|---|---|
Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation.
Topics: Adolescent; Antimanic Agents; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Bipolar | 2009 |
Proton magnetic resonance spectroscopy in youth with severe mood dysregulation.
Topics: Antimanic Agents; Arousal; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Bipolar Dis | 2008 |
Other Studies
9 other studies available for inositol and ADDH
| Article | Year |
|---|---|
Differentiating attention-deficit/hyperactivity disorder inattentive and combined types: a (1)H-magnetic resonance spectroscopy study of fronto-striato-thalamic regions.
Topics: Adolescent; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Choline; Corpus Striatum; | 2009 |
Neurochemical alterations in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder.
Topics: Adult; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Borderline Personality Disorder | 2010 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; | 2010 |
A cooperative interaction between LPHN3 and 11q doubles the risk for ADHD.
Topics: Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Brain; Case-Control Studies; Choline; | 2012 |
Analysis of brain metabolism by proton magnetic resonance spectroscopy (1H-MRS) in attention-deficit/hyperactivity disorder suggests a generalized differential ontogenic pattern from controls.
Topics: Adolescent; Adult; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Brain; Case-Control | 2012 |
1H MRSI of middle frontal gyrus in pediatric ADHD.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Choline; Creatine; Femal | 2013 |
Differences in brain chemistry in children and adolescents with attention deficit hyperactivity disorder with and without comorbid bipolar disorder: a proton magnetic resonance spectroscopy study.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Brain Chem | 2006 |
Reduced cingulate glutamate/glutamine-to-creatine ratios in adult patients with attention deficit/hyperactivity disorder -- a magnet resonance spectroscopy study.
Topics: Adult; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Choline; Creatine; Dominance, C | 2007 |
Striatal creatine and glutamate/glutamine in attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Choline; Co | 2007 |